Navigation Links
European Interventional Cardiology Device Market Will Remain Stable Through 2022 at Over $1.2 Billion
Date:11/6/2013

TORONTO, Nov. 6, 2013 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the maturing European interventional cardiology (IC) device market will be supported by the uptake of complex procedures as well as adoption of innovative premium-priced products. Although percutaneous coronary interventions (PCIs) are well accepted in Europe, the applications for these treatments are continuing to expand, supporting total procedure volumes. For example, more physicians are now performing PCIs to treat chronic total occlusions (CTOs), especially given that companies such as ASAHI INTECC and Abbott Laboratories have designed accessory devices specifically for this purpose.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36799LOGO )

The market will also be supported by growing acceptance of some premium-priced devices. For example, physicians are very enthusiastic about the potential for bioresorbable vascular scaffolds (BVS), which the body gradually absorbs, leaving no permanent hardware. Similarly, the European Society of Cardiology has recently released favorable recommendations for using drug-coated balloons (DCBs) for in-stent restenosis, as well as for using fractional flow reserve (FFR) guidewires.

"While the use of these products is growing, the extent of adoption will be determined in the next few years," said MRG Analyst Leila Bautista. "Right now, the high cost of these products is prohibitive for many facilities in Europe, and reimbursement is not ideal. There is no significant competitive pricing pressure either because the technology is so new that not that many companies offer these products yet. Nonetheless, if reimbursement improves or these products become more affordable, they have considerable potential in Europe."

The German and United Kingdom markets will have the most favorable environment for competitors through 2022 because of higher acceptance of premium-priced devices and more favorable reimbursement, respectively. By contrast, Spain and Italy have been most severely affected by the economic situation in Europe, resulting in hindered PCI volumes and drastic price declines. France lies in between, with its IC device market remaining fairly stable.

Millennium Research Group's European Markets for Interventional Cardiology Devices 2014 report includes unit, procedure, average selling price and revenue information, along with market drivers and limiters and a competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, accessory devices and intravascular imaging catheters and press guidewires in France, Germany, Italy, Spain and the United Kingdom.

About Millennium Research Group
Millennium Research Group (www.MRG.net), a Decision Resources Group company (www.DecisionResourcesGroup.com), is the global authority on medical technology market intelligence and the leading provider of strategic information to the healthcare sector. The company provides specialized industry expertise through multiclient market research, ongoing Marketrack™ projects, customer loyalty tracking, facility-level procedure forecasting, and customized solutions.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information, and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Christopher Comfort
Decision Resources Group
781-993-2597
ccomfort@dresources.com

Alex Jablokow
Millennium Research Group
617-599-8613
ajablokow@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HighPoint Solutions and InnoPeritus Partner to Provide Unprecedented Consultative Services in the European Life Sciences Market
2. US and European Regulators Accept for Review OMS302 Marketing Applications
3. Varians Calypso Tumor Tracking System Used in Lung, Stomach and Prostate Cancer Treatments at Leading European Cancer Center
4. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
7. Glysure Appoints Justine McQuillan as European Director of Clinical Affairs
8. Diabetes Alliance to Feature 17 Presentations for Linagliptin and Investigational Compound Empagliflozin^ During the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD)
9. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
10. European Market for Remote Patient Monitoring Applications
11. Harlan Laboratories Continues Strategic Growth with Expansion of South European Services Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):